161 related articles for article (PubMed ID: 34038868)
1. Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment.
Henriques TB; Dos Santos DZ; Dos Santos Guimarães I; Tessarollo NG; Lyra-Junior PCM; Mesquita P; Pádua D; Amaral AL; Cavadas B; Pereira L; Silva IV; Almeida RMDSG; Rangel LBA
Aging (Albany NY); 2021 May; 13(10):13405-13420. PubMed ID: 34038868
[TBL] [Abstract][Full Text] [Related]
2. Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway.
El-Kott AF; Shati AA; Al-Kahtani MA; Alqahtani S
Anal Cell Pathol (Amst); 2019; 2019():9627810. PubMed ID: 31360627
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
[TBL] [Abstract][Full Text] [Related]
4. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
5. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin.
Cheng Y; Mo F; Li Q; Han X; Shi H; Chen S; Wei Y; Wei X
Mol Cancer; 2021 Apr; 20(1):62. PubMed ID: 33814009
[TBL] [Abstract][Full Text] [Related]
6. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
8. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
9. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
10. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
11. Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.
Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287446
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation.
Park GY; Pathak HB; Godwin AK; Kwon Y
Cell Oncol (Dordr); 2021 Feb; 44(1):77-92. PubMed ID: 32910411
[TBL] [Abstract][Full Text] [Related]
13. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.
Duckworth C; Zhang L; Carroll SL; Ethier SP; Cheung HW
Oncogene; 2016 Aug; 35(31):4036-47. PubMed ID: 26657155
[TBL] [Abstract][Full Text] [Related]
15. γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
Li Y; Wu T; Wang Y; Yang L; Hu C; Chen L; Wu S
Gynecol Oncol; 2018 Apr; 149(1):163-172. PubMed ID: 29429592
[TBL] [Abstract][Full Text] [Related]
16. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
Jiang S; Chang H; Deng S; Fan D
Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
18. The CXCR2/CXCL2 signalling pathway - An alternative therapeutic approach in high-grade glioma.
Acker G; Zollfrank J; Jelgersma C; Nieminen-Kelhä M; Kremenetskaia I; Mueller S; Ghori A; Vajkoczy P; Brandenburg S
Eur J Cancer; 2020 Feb; 126():106-115. PubMed ID: 31927212
[TBL] [Abstract][Full Text] [Related]
19. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.
Zi D; Zhou ZW; Yang YJ; Huang L; Zhou ZL; He SM; He ZX; Zhou SF
Int J Mol Sci; 2015 Nov; 16(11):27228-51. PubMed ID: 26580601
[TBL] [Abstract][Full Text] [Related]
20. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
